NCT04390399 2025-12-15Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerImmunityBio, Inc.Phase 2 Active not recruiting328 enrolled
NCT03329248 2024-12-12QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyImmunityBio, Inc.Phase 1/2 Terminated6 enrolled 15 charts
NCT03586869 2024-08-27QUILT-3.080: NANT Pancreatic Cancer VaccineImmunityBio, Inc.Phase 1/2 Terminated3 enrolled 13 charts
NCT03127098 2024-08-06QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerNantCell, Inc.Phase 1/2 Terminated3 enrolled 6 charts
NCT03136406 2024-06-11QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyImmunityBio, Inc.Phase 1/2 Terminated3 enrolled 9 charts
NCT03387098 2024-05-22QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyImmunityBio, Inc.Phase 1/2 Terminated4 enrolled 9 charts